CUBAN CLINICAL TRIAL TO EVALUATE CANCER TREATMENT

The Center for Genetic Engineering and Biotec hnology (CIGB), based in Havana, Cuba, has initiated a Phase I trial to inhibit the protein kinase 2 phosphorylation.

The purpose of the trial is to assess the safety and performing a dose scale-up study of CIGB-300 in patients with cervical intraepithelial neoplasia and carcinoma in situ who have failed to respond to available treatments. CIGB-300 is a pro-apoptotic cyclic peptide that blocks the protein kinase 2 phosphorylation and exhibits antitumor effect in vivo.